XRF Scientific Limited reported a robust half-year performance ending December 2024, with revenue edging up 0.3% to $28.7 million and net profit after tax surging 11.8% to $5.0 million, driven by strong consumables sales and international growth.
PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.